| Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial T Powles, M Kockx, A Rodriguez-Vida, I Duran, SJ Crabb, ... Nature medicine 25 (11), 1706-1714, 2019 | 494 | 2019 |
| ctDNA guiding adjuvant immunotherapy in urothelial carcinoma T Powles, ZJ Assaf, N Davarpanah, R Banchereau, BE Szabados, ... Nature 595 (7867), 432-437, 2021 | 383 | 2021 |
| Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ T Powles, J Bellmunt, E Comperat, M De Santis, R Huddart, Y Loriot, ... Annals of Oncology 33 (3), 244-258, 2022 | 292 | 2022 |
| Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer B Szabados, N van Dijk, YZ Tang, MS van der Heijden, A Wimalasingham, ... European urology 73 (2), 149-152, 2018 | 106 | 2018 |
| Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder B Szabados, M Kockx, ZJ Assaf, PJ van Dam, A Rodriguez-Vida, I Duran, ... European Urology 82 (2), 212-222, 2022 | 81 | 2022 |
| Sodium storage in human tissues is mediated by glycosaminoglycan expression M Fischereder, B Michalke, E Schmöckel, A Habicht, R Kunisch, I Pavelic, ... American Journal of Physiology-Renal Physiology 313 (2), F319-F325, 2017 | 69 | 2017 |
| Cytokine-based cancer immunotherapy: Challenges and opportunities for IL-10 KS Rallis, AE Corrigan, H Dadah, AM George, SM Keshwara, M Sideris, ... Anticancer research 41 (7), 3247-3252, 2021 | 67 | 2021 |
| The impact of the COVID-19 pandemic on genitourinary cancer care: re-envisioning the future CJD Wallis, JWF Catto, A Finelli, AW Glaser, JL Gore, S Loeb, TM Morgan, ... European urology 78 (5), 731-742, 2020 | 66 | 2020 |
| Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer AG de Liano Lista, N van Dijk, GVO de Rueda, A Necchi, P Lavaud, ... European urology 77 (2), 269-276, 2020 | 47 | 2020 |
| The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma PC Barata, AG De Liano, P Mendiratta, V Crolley, B Szabados, L Morrison, ... British Journal of Cancer 119 (2), 160-163, 2018 | 46 | 2018 |
| Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor–targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell … R de Bruijn, A Wimalasingham, B Szabados, GD Stewart, SJ Welsh, ... European urology oncology 3 (2), 168-173, 2020 | 34 | 2020 |
| Outcomes for international metastatic renal cell carcinoma database consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell … MS Ernst, V Navani, JC Wells, F Donskov, N Basappa, C Labaki, SK Pal, ... European Urology 84 (1), 109-116, 2023 | 28 | 2023 |
| Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic … CL Gan, S Dudani, JC Wells, F Donskov, SK Pal, N Dizman, N Rathi, ... Cancer Medicine 10 (4), 1212-1221, 2021 | 28 | 2021 |
| Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after … A Bex, Y Abu-Ghanem, JV Van Thienen, N Graafland, B Lagerveld, ... Journal of Clinical Oncology 40 (6_suppl), 289-289, 2022 | 27 | 2022 |
| Toxicity and surgical complication rates of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer undergoing radical cystectomy: updated safety results from … B Szabados, A Rodriguez-Vida, I Durán, SJ Crabb, MS Van Der Heijden, ... European urology oncology 4 (3), 456-463, 2021 | 24 | 2021 |
| Clinical characteristics and outcome for four SARS-CoV-2-infected cancer patients treated with immune checkpoint inhibitors B Szabados, Y Abu-Ghanem, M Grant, J Choy, A Bex, T Powles European urology 78 (2), 276-280, 2020 | 21 | 2020 |
| Cytoreductive nephrectomy in the current treatment algorithm T Kuusk, B Szabados, WK Liu, T Powles, A Bex Therapeutic advances in medical oncology 11, 1758835919879026, 2019 | 21 | 2019 |
| Adverse effects and radiological manifestations of new immunotherapy agents YZ Tang, B Szabados, C Leung, A Sahdev The British Journal of Radiology 92 (1093), 20180164, 2019 | 21 | 2019 |
| Primary renal tumour response in patients treated with nivolumab and ipilimumab for metastatic renal cell carcinoma: real-world data assessment A Meerveld-Eggink, N Graafland, S Wilgenhof, JV Van Thienen, ... European Urology Open Science 35, 54-58, 2022 | 19 | 2022 |
| Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers GB Schulz, S Rodler, B Szabados, A Graser, A Buchner, C Stief, ... Journal of Geriatric Oncology 11 (7), 1061-1066, 2020 | 17 | 2020 |
